查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1371922

到 2030 年骨髓移植市場預測：按移植類型、適應症、最終用戶和地區進行的全球分析

Bone Marrow Transplant Market Forecasts to 2030 - Global Analysis By Transplant Type, Disease Indication, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC的數據，2023年全球骨髓移植市場規模為106.5億美元，預計2030年將達到153.9億美元，預測期內年複合成長率為5.4%。

長骨內部有稱為骨髓的軟骨組織。有兩種類型：造血幹細胞和間質幹細胞。骨髓的主要功能是造血、淋巴球生成和脂肪儲存。此外，骨髓移植（BMT）是治療某些癌症（如白血病和淋巴瘤）患者的獨特治療方法。幹細胞通常存在於骨髓中，在骨髓移植過程中取出、過濾，然後回到捐贈者（病人）或另一個人體內。

根據致力於根除癌症的志願組織美國癌症協會 2022 年 1 月提供的資料，非何傑金氏淋巴瘤(NHL) 是美國最常見的癌症之一，佔所有癌症的大多數。約佔4%。

血液疾病增加

白血病、淋巴瘤和多發性骨髓瘤等血液疾病在世界上變得越來越常見。環境暴露、生活方式的改變和高齡化都會產生影響。此外，診斷和早期檢測技術的改進使更多病例更早檢測，並增加了人們對骨髓移植作為潛在治療和治癒方法的興趣。此外，由於標靶治療和精準醫療技術的發展，可以從移植中受益的患者數量不斷增加，這些技術可以與移植相結合以改善治療效果。

昂貴的移植費用

骨髓移植市場的主要障礙之一是移植成本高。移植前評估、預處理方案、實際移植、移植後照護和長期追蹤都是昂貴的程序。對於許多患者來說，即使在醫療保健系統高度發展的地區，這些費用也可能成為治療的障礙。此外，保險並不總是涵蓋全部費用，這給患者帶來了沉重的財務負擔。

個人化醫療的現代化

骨髓移植領域受到基因組和分子分析驅動的個人化醫療的極大影響。透過根據個人的遺傳和分子特徵量身訂做移植策略和移植後治療，可以改善移植結果並減少併發症。此外，該策略減少了副作用，同時提高了移植的整體療效。

醫療費用和財務限制

骨髓移植對病患和醫療保健系統帶來的巨大經濟負擔是骨髓移植市場的主要威脅之一。移植前評估、預處理方案、實際移植、移植後護理和長期追蹤的高昂費用可能導致許多患者選擇不接受移植。此外，高昂的醫療費用可能會對保險系統造成壓力，並阻止服務不足的人口接受移植手術。

COVID-19 的影響：

COVID-19大流行對骨髓移植市場產生了重大影響。全球醫療保健系統受到疫情影響，非緊急移植手術被推遲或取消，以節省醫療資源並降低弱勢患者的感染風險。然而，人們對移植受者免疫力缺乏功能低下狀況的擔憂日益增加，需要採取嚴格的感染控制措施並修改移植方案。

預計在預測期內，白血病領域將是最大的。

白血病在骨髓移植市場中佔據最大的市場佔有率。骨髓移植最常見且眾所周知的原因之一是白血病，其特徵是白血球異常增生。各種類型白血病的高患病，包括急性淋巴性白血病（ALL）、急性骨髓性白血病（AML）和慢性骨髓性白血病（CML），顯著增加了移植服務的需求。此外，移植方法、支持治療和標靶治療的改進也提高了白血病患者的成功率，進一步推動了該市場的擴張。

預計門診手術中心部門在預測期內年複合成長率最高

在骨髓移植市場中，門診手術中心（ASC）領域維持最高的年複合成長率。 ASC 提供各種門診外科手術，包括一些藥物治療和微創手術。 ASC 越來越受歡迎，因為它們提供負擔得起且實用的醫療保健、住院時間短和感染風險低。此外，ASC 最近已擴展到提供各種服務，包括整形外科、眼科、胃腸病學、疼痛管理和許多其他領域。

比最大的地區

北美地區佔據骨髓移植最大的市場佔有率。這一優勢得益於多種要素，包括強力的法規環境、完善的醫療基礎設施、需要骨髓移植的血液疾病的高患病以及尖端的醫療技術。此外，北美受益於廣泛的研究和開發工作、高額醫療支出和龐大的捐助者庫。該地區的市場領導地位也得益於患者和醫療保健提供者對骨髓移植益處的認知不斷提高。

複合年複合成長率最高的地區：

骨髓移植市場年複合成長率最高的是中東和北非（MENA）地區。這一成長的推動因素包括醫療保健投資的增加、醫療保健基礎設施的改善以及公眾對骨髓移植等最先進治療的認知的提高。此外，阿拉伯聯合大公國、沙烏地阿拉伯和卡達等中東和北非國家顯著改善了醫療基礎設施，使其公民更容易接受骨髓移植。對移植服務的需求不斷成長也是由於該地區血液疾病的患病不斷上升，從而推動了市場的擴張。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球骨髓移植市場：依移植類型分類

  • 自體骨髓移植
  • 同種異體骨髓移植
  • 其他類型的移植

第6章 全球骨髓移植市場：依疾病適應症

  • 白血病
  • 淋巴瘤
  • 骨髓瘤
  • 地中海型貧血
  • 骨髓發育不良症候群
  • 骨髓增生性疾病
  • 再生障礙性貧血
  • 固態腫瘤
  • 鐮狀細胞性貧血
  • 其他疾病的適應症

第7章 全球骨髓移植市場：依最終用戶分類

  • 醫院
  • 多專科診所
  • 門診手術中心
  • 其他最終用戶

第8章 全球骨髓移植市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Gamida Cell Ltd.
  • Mesoblast Ltd.
  • American Type Culture Collection（ATCC）Inc
  • Lonza Group Ltd.
  • FUJIFILM Cellular Dynamics, Inc.
  • ReachBio LLC.
  • Sanofi-Aventis LLC.
  • PromoCell GmbH
  • Abbott Laboratories Inc
  • The Emmes Company LLC
  • CORESTEM, Inc.
  • StemCell Technologies.
  • Hemacare Corporation
  • AllCells LLC.
  • Lifeline Cell Technology LLC
  • ReeLabs Pvt. Ltd.
  • Charles River Laboratories
  • Merck Millipore Corporation
Product Code: SMRC23979

According to Stratistics MRC, the Global Bone Marrow Transplant Market is accounted for $10.65 billion in 2023 and is expected to reach $15.39 billion by 2030 growing at a CAGR of 5.4% during the forecast period. In the interior of long bones, there is a soft vascular tissue called bone marrow. Hematopoietic and mesenchymal stem cells make up both types of stem cells. The main functions of bone marrow are hematopoiesis, lymphocyte production, and fat storage. Additionally, a unique form of treatment for people with certain cancers, such as leukemia, lymphoma, or other conditions, is bone marrow transplantation (BMT). Stem cells that are typically found in the bone marrow are removed during a bone marrow transplant, filtered, and then returned to the donor (patient) or to another individual.

According to data provided by the American Cancer Society, Inc., a voluntary health organization dedicated to eliminating cancer, in January 2022, Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the U.S., accounting for about 4% of all cancers.

Market Dynamics:

Driver:

Increasing incidence of haematological disorders

Hematological disorders like leukemia, lymphoma, and multiple myeloma are becoming more commonplace in the world. Environmental exposures, alterations in lifestyle, and an aging population all play a role. Furthermore, as a result of improvements in diagnostics and early detection techniques, more cases are now being discovered at an earlier stage, which has raised interest in bone marrow transplantation as a potential treatment or cure. The number of patients who can benefit from transplantation has also increased as a result of the development of targeted therapies and precision medicine techniques, which can be combined with transplants to improve outcomes.

Restraint:

High transplantation costs

The high price of the procedure is one of the main barriers to the market for bone marrow transplants. The evaluation prior to the transplant, the conditioning regimens, the actual transplant, the post-transplant care, and long-term follow-up are all expensive procedures. Many patients may find these costs to be a barrier to care, even in areas with highly developed healthcare systems. Additionally, insurance might not always pay the full cost, leaving patients with sizable financial burdens.

Opportunity:

Modernization of personalized medicine

The field of bone marrow transplantation is greatly impacted by personalized medicine, which is driven by genomic and molecular profiling. Based on a person's genetic and molecular profile, it is possible to improve transplant outcomes and lower complications by customizing transplant strategies and post-transplant therapies. Moreover, this strategy reduces negative effects while improving the general efficacy of transplantation.

Threat:

Healthcare costs and economic constraints

The significant financial burden it places on patients and healthcare systems is one of the main threats to the bone marrow transplant market. Many patients may choose not to undergo transplantation due to the high costs involved, including those of pre-transplant evaluation, conditioning regimens, the actual transplantation, post-transplant care, and long-term follow-up. Additionally, high medical expenses can also put a strain on insurance plans and prevent underserved populations from receiving transplants.

COVID-19 Impact:

On the market for bone marrow transplants, the COVID-19 pandemic had a sizable effect. Worldwide healthcare systems were affected by the pandemic, which included the postponement or cancellation of non-urgent transplant procedures in order to conserve healthcare resources and reduce infection risks for susceptible patients. However, as concerns about transplant recipients Immuno-compromised states increased, strict infection control measures and modifications to transplant protocols became necessary.

The Leukemia segment is expected to be the largest during the forecast period

In the bone marrow transplant market, leukemia holds the largest market share. One of the most common and well-known causes of bone marrow transplantation is leukemia, which is characterized by the abnormal proliferation of white blood cells. The high prevalence of different leukemia types, such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML), significantly increases the demand for transplantation services. Moreover, the success rates for leukemia patients have also improved thanks to improvements in transplant methods, supportive care, and targeted therapies, which have further fueled this market's expansion.

The Ambulatory Surgical Centers segment is expected to have the highest CAGR during the forecast period

The bone marrow transplant market's, Ambulatory Surgical Centers (ASCs) segment holds the highest CAGR. ASCs provide a variety of outpatient surgical procedures, including some medical treatments and minimally invasive surgeries. Their growing popularity is a result of their capacity to offer affordable and practical healthcare, shorter hospital stays, and lower infection risks. Additionally, ASCs have diversified their offerings in recent years to include a number of specialties, such as orthopedics, ophthalmology, gastroenterology, and pain management.

Region with largest share:

The North American region holds the largest market share for bone marrow transplants. This dominance can be attributed to a number of things, including a strong regulatory environment, an established healthcare infrastructure, a high prevalence of haematological disorders requiring bone marrow transplants, and cutting-edge medical technologies. Additionally, North America benefits from extensive research and development efforts, significant healthcare expenditures, and a sizable donor pool. The region's market leadership has also been aided by growing patient and healthcare provider awareness of the advantages of bone marrow transplantation.

Region with highest CAGR:

The market for bone marrow transplants has seen the highest CAGR in the Middle East and North Africa (MENA) region. Increased healthcare investments, a growing healthcare infrastructure, and rising public awareness of cutting-edge treatments like bone marrow transplants are a few of the factors driving this growth. Moreover, the United Arab Emirates, Saudi Arabia, and Qatar are among the MENA nations that have made significant improvements to their healthcare infrastructure, enabling their populations to access bone marrow transplantation more easily. The rising demand for transplantation services is also a result of the region's increasing prevalence of haematological disorders, which is fueling the market's expansion.

Key players in the market:

Some of the key players in Bone Marrow Transplant market include: Gamida Cell Ltd., Mesoblast Ltd., American Type Culture Collection (ATCC) Inc, Lonza Group Ltd., FUJIFILM Cellular Dynamics, Inc., ReachBio LLC., Sanofi-Aventis LLC., PromoCell GmbH, Abbott Laboratories Inc, The Emmes Company LLC, CORESTEM, Inc., StemCell Technologies., Hemacare Corporation, AllCells LLC., Lifeline Cell Technology LLC, ReeLabs Pvt. Ltd., Charles River Laboratories and Merck Millipore Corporation .

Key Developments:

In June 2023, Lonza, a trusted partner of the pharmaceutical, biotech, and nutrition industries, has entered into a ten-year Virtual Power Purchase Agreement with IGNIS. A VPPA represents a tailored and adaptable solution that caters to the needs of companies like Lonza, which operates in multiple sites. Unlike traditional power purchase agreements, VPPAs offer more flexibility and attract investments in the solar electricity production facilities as they are not linked to photovoltaic production facilities through physical grids.

In January 2023, FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced today that it has entered an agreement to grant global healthcare company Novo Nordisk A/S a non-exclusive right to use FUJIFILM Cellular Dynamics' iPSC platform for the development and commercialization of iPSC-derived cell therapies with a focus on addressing serious chronic diseases.

In October 2020, Gamida Cell Ltd., a leading cellular and immune therapeutics company, and Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced an expansion of their existing strategic collaboration for omidubicel, Gamida Cell's advanced cell therapy in Phase 3 clinical development as a potentially life-saving treatment option for patients in need of an allogeneic hematopoietic stem cell transplant.

Transplant Types Covered:

  • Autologous Bone Marrow Transplant
  • Allogeneic Bone marrow Transplant
  • Other Transplant Types

Disease Indications Covered:

  • Leukemia
  • Lymphoma
  • Myeloma
  • Thalassemia
  • Myelodysplastic Syndrome
  • Myeloproliferative Disorders
  • Aplastic Anemia
  • Solid Tumors
  • Sickle cell Anemia
  • Other Disease Indications

End Users Covered:

  • Hospitals
  • Multispecialty Clinics
  • Ambulatory Surgical Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Bone Marrow Transplant Market, By Transplant Type

  • 5.1 Introduction
  • 5.2 Autologous Bone Marrow Transplant
  • 5.3 Allogeneic Bone marrow Transplant
  • 5.4 Other Transplant Types

6 Global Bone Marrow Transplant Market, By Disease Indication

  • 6.1 Introduction
  • 6.2 Leukemia
  • 6.3 Lymphoma
  • 6.4 Myeloma
  • 6.5 Thalassemia
  • 6.6 Myelodysplastic Syndrome
  • 6.7 Myeloproliferative Disorders
  • 6.8 Aplastic Anemia
  • 6.9 Solid Tumors
  • 6.10 Sickle cell Anemia
  • 6.11 Other Disease Indications

7 Global Bone Marrow Transplant Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Multispecialty Clinics
  • 7.4 Ambulatory Surgical Centers
  • 7.5 Other End Users

8 Global Bone Marrow Transplant Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Gamida Cell Ltd.
  • 10.2 Mesoblast Ltd.
  • 10.3 American Type Culture Collection (ATCC) Inc
  • 10.4 Lonza Group Ltd.
  • 10.5 FUJIFILM Cellular Dynamics, Inc.
  • 10.6 ReachBio LLC.
  • 10.7 Sanofi-Aventis LLC.
  • 10.8 PromoCell GmbH
  • 10.9 Abbott Laboratories Inc
  • 10.10 The Emmes Company LLC
  • 10.11 CORESTEM, Inc.
  • 10.12 StemCell Technologies.
  • 10.13 Hemacare Corporation
  • 10.14 AllCells LLC.
  • 10.15 Lifeline Cell Technology LLC
  • 10.16 ReeLabs Pvt. Ltd.
  • 10.17 Charles River Laboratories
  • 10.18 Merck Millipore Corporation

List of Tables

  • Table 1 Global Bone Marrow Transplant Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Bone Marrow Transplant Market Outlook, By Transplant Type (2021-2030) ($MN)
  • Table 3 Global Bone Marrow Transplant Market Outlook, By Autologous Bone Marrow Transplant (2021-2030) ($MN)
  • Table 4 Global Bone Marrow Transplant Market Outlook, By Allogeneic Bone marrow Transplant (2021-2030) ($MN)
  • Table 5 Global Bone Marrow Transplant Market Outlook, By Other Transplant Types (2021-2030) ($MN)
  • Table 6 Global Bone Marrow Transplant Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 7 Global Bone Marrow Transplant Market Outlook, By Leukemia (2021-2030) ($MN)
  • Table 8 Global Bone Marrow Transplant Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 9 Global Bone Marrow Transplant Market Outlook, By Myeloma (2021-2030) ($MN)
  • Table 10 Global Bone Marrow Transplant Market Outlook, By Thalassemia (2021-2030) ($MN)
  • Table 11 Global Bone Marrow Transplant Market Outlook, By Myelodysplastic Syndrome (2021-2030) ($MN)
  • Table 12 Global Bone Marrow Transplant Market Outlook, By Myeloproliferative Disorders (2021-2030) ($MN)
  • Table 13 Global Bone Marrow Transplant Market Outlook, By Aplastic Anemia (2021-2030) ($MN)
  • Table 14 Global Bone Marrow Transplant Market Outlook, By Solid Tumors (2021-2030) ($MN)
  • Table 15 Global Bone Marrow Transplant Market Outlook, By Sickle cell Anemia (2021-2030) ($MN)
  • Table 16 Global Bone Marrow Transplant Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 17 Global Bone Marrow Transplant Market Outlook, By End User (2021-2030) ($MN)
  • Table 18 Global Bone Marrow Transplant Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 19 Global Bone Marrow Transplant Market Outlook, By Multispecialty Clinics (2021-2030) ($MN)
  • Table 20 Global Bone Marrow Transplant Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 21 Global Bone Marrow Transplant Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 22 North America Bone Marrow Transplant Market Outlook, By Country (2021-2030) ($MN)
  • Table 23 North America Bone Marrow Transplant Market Outlook, By Transplant Type (2021-2030) ($MN)
  • Table 24 North America Bone Marrow Transplant Market Outlook, By Autologous Bone Marrow Transplant (2021-2030) ($MN)
  • Table 25 North America Bone Marrow Transplant Market Outlook, By Allogeneic Bone marrow Transplant (2021-2030) ($MN)
  • Table 26 North America Bone Marrow Transplant Market Outlook, By Other Transplant Types (2021-2030) ($MN)
  • Table 27 North America Bone Marrow Transplant Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 28 North America Bone Marrow Transplant Market Outlook, By Leukemia (2021-2030) ($MN)
  • Table 29 North America Bone Marrow Transplant Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 30 North America Bone Marrow Transplant Market Outlook, By Myeloma (2021-2030) ($MN)
  • Table 31 North America Bone Marrow Transplant Market Outlook, By Thalassemia (2021-2030) ($MN)
  • Table 32 North America Bone Marrow Transplant Market Outlook, By Myelodysplastic Syndrome (2021-2030) ($MN)
  • Table 33 North America Bone Marrow Transplant Market Outlook, By Myeloproliferative Disorders (2021-2030) ($MN)
  • Table 34 North America Bone Marrow Transplant Market Outlook, By Aplastic Anemia (2021-2030) ($MN)
  • Table 35 North America Bone Marrow Transplant Market Outlook, By Solid Tumors (2021-2030) ($MN)
  • Table 36 North America Bone Marrow Transplant Market Outlook, By Sickle cell Anemia (2021-2030) ($MN)
  • Table 37 North America Bone Marrow Transplant Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 38 North America Bone Marrow Transplant Market Outlook, By End User (2021-2030) ($MN)
  • Table 39 North America Bone Marrow Transplant Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 40 North America Bone Marrow Transplant Market Outlook, By Multispecialty Clinics (2021-2030) ($MN)
  • Table 41 North America Bone Marrow Transplant Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 42 North America Bone Marrow Transplant Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 43 Europe Bone Marrow Transplant Market Outlook, By Country (2021-2030) ($MN)
  • Table 44 Europe Bone Marrow Transplant Market Outlook, By Transplant Type (2021-2030) ($MN)
  • Table 45 Europe Bone Marrow Transplant Market Outlook, By Autologous Bone Marrow Transplant (2021-2030) ($MN)
  • Table 46 Europe Bone Marrow Transplant Market Outlook, By Allogeneic Bone marrow Transplant (2021-2030) ($MN)
  • Table 47 Europe Bone Marrow Transplant Market Outlook, By Other Transplant Types (2021-2030) ($MN)
  • Table 48 Europe Bone Marrow Transplant Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 49 Europe Bone Marrow Transplant Market Outlook, By Leukemia (2021-2030) ($MN)
  • Table 50 Europe Bone Marrow Transplant Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 51 Europe Bone Marrow Transplant Market Outlook, By Myeloma (2021-2030) ($MN)
  • Table 52 Europe Bone Marrow Transplant Market Outlook, By Thalassemia (2021-2030) ($MN)
  • Table 53 Europe Bone Marrow Transplant Market Outlook, By Myelodysplastic Syndrome (2021-2030) ($MN)
  • Table 54 Europe Bone Marrow Transplant Market Outlook, By Myeloproliferative Disorders (2021-2030) ($MN)
  • Table 55 Europe Bone Marrow Transplant Market Outlook, By Aplastic Anemia (2021-2030) ($MN)
  • Table 56 Europe Bone Marrow Transplant Market Outlook, By Solid Tumors (2021-2030) ($MN)
  • Table 57 Europe Bone Marrow Transplant Market Outlook, By Sickle cell Anemia (2021-2030) ($MN)
  • Table 58 Europe Bone Marrow Transplant Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 59 Europe Bone Marrow Transplant Market Outlook, By End User (2021-2030) ($MN)
  • Table 60 Europe Bone Marrow Transplant Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 61 Europe Bone Marrow Transplant Market Outlook, By Multispecialty Clinics (2021-2030) ($MN)
  • Table 62 Europe Bone Marrow Transplant Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 63 Europe Bone Marrow Transplant Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 64 Asia Pacific Bone Marrow Transplant Market Outlook, By Country (2021-2030) ($MN)
  • Table 65 Asia Pacific Bone Marrow Transplant Market Outlook, By Transplant Type (2021-2030) ($MN)
  • Table 66 Asia Pacific Bone Marrow Transplant Market Outlook, By Autologous Bone Marrow Transplant (2021-2030) ($MN)
  • Table 67 Asia Pacific Bone Marrow Transplant Market Outlook, By Allogeneic Bone marrow Transplant (2021-2030) ($MN)
  • Table 68 Asia Pacific Bone Marrow Transplant Market Outlook, By Other Transplant Types (2021-2030) ($MN)
  • Table 69 Asia Pacific Bone Marrow Transplant Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 70 Asia Pacific Bone Marrow Transplant Market Outlook, By Leukemia (2021-2030) ($MN)
  • Table 71 Asia Pacific Bone Marrow Transplant Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 72 Asia Pacific Bone Marrow Transplant Market Outlook, By Myeloma (2021-2030) ($MN)
  • Table 73 Asia Pacific Bone Marrow Transplant Market Outlook, By Thalassemia (2021-2030) ($MN)
  • Table 74 Asia Pacific Bone Marrow Transplant Market Outlook, By Myelodysplastic Syndrome (2021-2030) ($MN)
  • Table 75 Asia Pacific Bone Marrow Transplant Market Outlook, By Myeloproliferative Disorders (2021-2030) ($MN)
  • Table 76 Asia Pacific Bone Marrow Transplant Market Outlook, By Aplastic Anemia (2021-2030) ($MN)
  • Table 77 Asia Pacific Bone Marrow Transplant Market Outlook, By Solid Tumors (2021-2030) ($MN)
  • Table 78 Asia Pacific Bone Marrow Transplant Market Outlook, By Sickle cell Anemia (2021-2030) ($MN)
  • Table 79 Asia Pacific Bone Marrow Transplant Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 80 Asia Pacific Bone Marrow Transplant Market Outlook, By End User (2021-2030) ($MN)
  • Table 81 Asia Pacific Bone Marrow Transplant Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 82 Asia Pacific Bone Marrow Transplant Market Outlook, By Multispecialty Clinics (2021-2030) ($MN)
  • Table 83 Asia Pacific Bone Marrow Transplant Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 84 Asia Pacific Bone Marrow Transplant Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 85 South America Bone Marrow Transplant Market Outlook, By Country (2021-2030) ($MN)
  • Table 86 South America Bone Marrow Transplant Market Outlook, By Transplant Type (2021-2030) ($MN)
  • Table 87 South America Bone Marrow Transplant Market Outlook, By Autologous Bone Marrow Transplant (2021-2030) ($MN)
  • Table 88 South America Bone Marrow Transplant Market Outlook, By Allogeneic Bone marrow Transplant (2021-2030) ($MN)
  • Table 89 South America Bone Marrow Transplant Market Outlook, By Other Transplant Types (2021-2030) ($MN)
  • Table 90 South America Bone Marrow Transplant Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 91 South America Bone Marrow Transplant Market Outlook, By Leukemia (2021-2030) ($MN)
  • Table 92 South America Bone Marrow Transplant Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 93 South America Bone Marrow Transplant Market Outlook, By Myeloma (2021-2030) ($MN)
  • Table 94 South America Bone Marrow Transplant Market Outlook, By Thalassemia (2021-2030) ($MN)
  • Table 95 South America Bone Marrow Transplant Market Outlook, By Myelodysplastic Syndrome (2021-2030) ($MN)
  • Table 96 South America Bone Marrow Transplant Market Outlook, By Myeloproliferative Disorders (2021-2030) ($MN)
  • Table 97 South America Bone Marrow Transplant Market Outlook, By Aplastic Anemia (2021-2030) ($MN)
  • Table 98 South America Bone Marrow Transplant Market Outlook, By Solid Tumors (2021-2030) ($MN)
  • Table 99 South America Bone Marrow Transplant Market Outlook, By Sickle cell Anemia (2021-2030) ($MN)
  • Table 100 South America Bone Marrow Transplant Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 101 South America Bone Marrow Transplant Market Outlook, By End User (2021-2030) ($MN)
  • Table 102 South America Bone Marrow Transplant Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 103 South America Bone Marrow Transplant Market Outlook, By Multispecialty Clinics (2021-2030) ($MN)
  • Table 104 South America Bone Marrow Transplant Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 105 South America Bone Marrow Transplant Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 106 Middle East & Africa Bone Marrow Transplant Market Outlook, By Country (2021-2030) ($MN)
  • Table 107 Middle East & Africa Bone Marrow Transplant Market Outlook, By Transplant Type (2021-2030) ($MN)
  • Table 108 Middle East & Africa Bone Marrow Transplant Market Outlook, By Autologous Bone Marrow Transplant (2021-2030) ($MN)
  • Table 109 Middle East & Africa Bone Marrow Transplant Market Outlook, By Allogeneic Bone marrow Transplant (2021-2030) ($MN)
  • Table 110 Middle East & Africa Bone Marrow Transplant Market Outlook, By Other Transplant Types (2021-2030) ($MN)
  • Table 111 Middle East & Africa Bone Marrow Transplant Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 112 Middle East & Africa Bone Marrow Transplant Market Outlook, By Leukemia (2021-2030) ($MN)
  • Table 113 Middle East & Africa Bone Marrow Transplant Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 114 Middle East & Africa Bone Marrow Transplant Market Outlook, By Myeloma (2021-2030) ($MN)
  • Table 115 Middle East & Africa Bone Marrow Transplant Market Outlook, By Thalassemia (2021-2030) ($MN)
  • Table 116 Middle East & Africa Bone Marrow Transplant Market Outlook, By Myelodysplastic Syndrome (2021-2030) ($MN)
  • Table 117 Middle East & Africa Bone Marrow Transplant Market Outlook, By Myeloproliferative Disorders (2021-2030) ($MN)
  • Table 118 Middle East & Africa Bone Marrow Transplant Market Outlook, By Aplastic Anemia (2021-2030) ($MN)
  • Table 119 Middle East & Africa Bone Marrow Transplant Market Outlook, By Solid Tumors (2021-2030) ($MN)
  • Table 120 Middle East & Africa Bone Marrow Transplant Market Outlook, By Sickle cell Anemia (2021-2030) ($MN)
  • Table 121 Middle East & Africa Bone Marrow Transplant Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 122 Middle East & Africa Bone Marrow Transplant Market Outlook, By End User (2021-2030) ($MN)
  • Table 123 Middle East & Africa Bone Marrow Transplant Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 124 Middle East & Africa Bone Marrow Transplant Market Outlook, By Multispecialty Clinics (2021-2030) ($MN)
  • Table 125 Middle East & Africa Bone Marrow Transplant Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 126 Middle East & Africa Bone Marrow Transplant Market Outlook, By Other End Users (2021-2030) ($MN)